# Compare NAD+, Ipamorelin, CJC-1295 and MOTS-c — pureformpeptide

> Side-by-side comparison of four growth-hormone axis and longevity research compounds: NAD+, Ipamorelin, CJC-1295 and MOTS-c — class, mechanism, evidence maturity, regulatory and WADA status.

Where the GH axis and longevity biology meet — and how far apart the four compounds actually are in their evidence, their regulation, and their clinical footprints.

## The short version

This page lines up [NAD+](/nad), [Ipamorelin](/ipamorelin), [CJC-1295](/cjc-1295), and [MOTS-c](/mots-c) on the dimensions that most matter when reading their research: compound class, primary mechanism, what species and models have been studied, how strong the human evidence is, regulatory status, and the single most important caveat for each. The headline: NAD+ (via NMN/NR precursors) has the most human trial data of the four; CJC-1295 has well-characterized human pharmacokinetics but a failed development program; Ipamorelin has a null Phase 2 RCT; and MOTS-c has zero interventional human data. None is an approved medicine for longevity or GH-axis indications. None is presented here with a human dose or protocol recommendation.

## The comparison matrix

| Dimension | NAD+ | Ipamorelin | CJC-1295 | MOTS-c |
| --- | --- | --- | --- | --- |
| Compound class | Endogenous dinucleotide / DietarySupplement | Synthetic pentapeptide / GHS-R1a agonist | Synthetic GHRH analog (hGRF(1-29) tetrasubstituted) | Mitochondrial-derived 16-aa peptide (MT-RNR1-encoded) |
| Primary mechanism | Redox electron carrier; NAD+-dependent sirtuin/PARP substrate | Pulsatile GH secretion via GHS-R1a on pituitary somatotrophs | Sustained GH/IGF-1 elevation via GHRHR (Gs/cAMP/PKA); albumin binding (DAC) extends half-life to ~6 days | AMPK activation via folate-cycle/AICAR; nuclear translocation under stress; CK2 direct binding |
| Evidence base — human | Multicenter RCTs (NMN/NR precursors); physiological human outcomes in specific populations [11][12][13] | Phase 2 RCT (n=114, null result); acute IV PK/PD in healthy volunteers [3][4] | Two PK/PD studies in healthy adults (n=11, n=30); serum proteome study [8][9][10] | Observational biomarker association only (n=94, hemodialysis cohort) [19]; zero interventional human studies |
| Evidence base — animal | CD38 knockout mice; murine HFpEF cardiac rescue [16][17] | Rat bone growth, ferret weight-loss model; GHS-R1a class cardiotoxicity (related compound, rat) [1][2][5] | Small human PK studies are the primary data; LC-MS/MS anti-doping identification [7] | Mouse performance, atrophy, and glucose-uptake studies; cell-free CK2 binding [18][21] |
| Regulatory status | Dietary supplement (NMN/NR); IV form compounded (FDA Class I recall for endotoxin) | Research chemical; not approved; removed from 503A list 2024; prohibited WADA S2 | Research chemical; not approved; 503A not recommended 2024; prohibited WADA S2 | Research chemical; not approved; prohibited WADA/USADA |
| Key caution | Human efficacy beyond blood NAD+ elevation is inconsistent; IV form carries contamination risk [11] | Only human efficacy trial was null; long-term safety data absent [3] | Development discontinued; immunogenicity concern raised by FDA; DAC/no-DAC confusion widespread [6][9] | All interventional evidence is preclinical; no human PK; no human dose established [20] |

## Compound class

The four span three distinct biochemical categories. NAD+ is an endogenous dinucleotide — the oxidized coenzyme present in every living cell, supplemented via NMN or NR precursors because oral NAD+ itself is poorly absorbed. Ipamorelin is a synthetic pentapeptide; CJC-1295 is a synthetic 29-amino-acid GHRH analog (with or without a Drug Affinity Complex albumin-binding arm). MOTS-c is in a category of its own: a 16-amino-acid peptide encoded not by nuclear DNA but by the mitochondrial genome itself [20].

The regulatory consequences flow directly from class: NAD+ is sold as a dietary supplement; the two GH secretagogues are research chemicals that regulators have specifically declined to permit in compounding; MOTS-c is a research chemical with no approval pathway opened.

## Mechanism

NAD+ is the broadest-acting of the four: it powers mitochondrial oxidative phosphorylation, is consumed by sirtuins (gene regulation, stress response) and by PARP1 (DNA repair), and its depletion by CD38 with age is the central mechanistic rationale for the entire supplement category [14][16].

Ipamorelin acts at a single receptor (GHS-R1a) to amplify the pituitary's own GH pulse mechanism — brief, targeted, and selective compared to earlier secretagogues [4]. CJC-1295 acts at the GHRH receptor (GHRHR) — a different molecular target, a sustained elevation rather than a discrete pulse, and with the DAC form's albumin-binding giving days of pharmacological activity per dose [9][10].

MOTS-c's mechanism is the most indirect: it inhibits the folate cycle to accumulate AICAR, which then activates AMPK — the same energy sensor that responds to low cellular ATP during exercise or fasting. Under stress it also moves to the nucleus to regulate antioxidant gene networks [22]. It is an intracellular retrograde signal, not a receptor agonist.

## Evidence maturity

NAD+ precursors are the most clinically tested of the four. NR has a dose-escalation placebo-controlled safety and pharmacology trial [15]; NMN has a multicenter RCT with functional outcome measures [12] and a controlled insulin-sensitivity study in a defined population [13]. The 2025 *Nature Metabolism* review provides a critical synthesis: blood NAD+ elevation is reliable; hard clinical outcomes remain inconsistent [11].

CJC-1295 has characterized human PK/PD in two publications — sustained GH/IGF-1 elevation with preserved pulsatility is well-described [9][10] — but the development program was discontinued and the 2025 pharmacology review provides the current field context [6].

Ipamorelin has the cleanest preclinical selectivity story and two human datasets (acute IV PK [4] and a Phase 2 RCT [3]) — but the RCT was null, and no further human development followed.

MOTS-c has the weakest interventional evidence base: mouse studies [18][21], human cell work [22], and one observational human biomarker study [19]. Zero controlled human interventions.

## Regulatory and WADA status

None of the four is approved as a medicine for longevity, GH augmentation, or any related indication. NAD+ is unique in being sold as a dietary supplement with legal market access (though NMN's supplement status is contested by the FDA). The two GH secretagogues — Ipamorelin and CJC-1295 — were both reviewed at the 2024 FDA Pharmacy Compounding Advisory Committee and were not recommended for the 503A bulk substances list, citing safety concerns including immunogenicity for CJC-1295 [6]. Both are prohibited at all times in sport under WADA Section S2 (peptide hormones, growth factors, and related substances); anti-doping detection methods are established for both [7].

MOTS-c is prohibited in elite sport (WADA/USADA peptide/metabolic modulator categories) with research-chemical-only status globally. NAD+ and NMN/NR precursors are explicitly not prohibited by WADA.

---

An independent literature desk for the growth-hormone axis and longevity research — what the peer-reviewed record actually shows, stated plainly and cited precisely.